The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specializes or retains ...

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each ...

Researchers are investigating the potential of CRISPR in relation to Down syndrome.

Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, ...

Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...

The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human effort in the realm of scientific discovery, adding to a growing debate ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...